July 8, 2008
Evolence: Will this New "Advanced" Collagen Filler Take Hold?
Analysis of:
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler | www.investor.jnj.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: Evolence is an injectable filler material that is made by an "advanced collagen GLYMATRIX™ Technology." Collagen has generally fallen out of favor amongst aesthetic physicians due to its short duration of action. Evolence will have to demonstrate that it is superior to the plethora of other injectable filler materials currently available to gain market share. To do so will not only require clinical efficacy, it will also require a tremendous marketing effort to penetrate a market where there is no shortage of injectable filler materials from which to choose.
Analysis: The market currently has a variety of injectable filler materials from which to choose. The leaders are hyaluronic acid-based materials such as Restylane/Perlane (Medicis) and Juvederm Ultra/Juvederm Ultra Plus (Allergan). Other fillers that are widely used include Radiesse (BioForm) and Scultpra (Dermik/Sanofi-Aventis). Artefill (Artes Medical) is also used, though not as widely due to many concerns due to its permanence. Evolence introduces collagen back into the market. Previously, collagen based products either required allergy testing (e.g., Zyderm/Zyplast) or were relatively short in its duration of effect (e.g., CosmoDerm/CosmoPlast). If Evolence can demonstrate some superiority over the plethora of products currently available, it may gain some market share. However, to do so will require a tremendous marketing effort and potential financial incentives as well.
Analysis: The market currently has a variety of injectable filler materials from which to choose. The leaders are hyaluronic acid-based materials such as Restylane/Perlane (Medicis) and Juvederm Ultra/Juvederm Ultra Plus (Allergan). Other fillers that are widely used include Radiesse (BioForm) and Scultpra (Dermik/Sanofi-Aventis). Artefill (Artes Medical) is also used, though not as widely due to many concerns due to its permanence. Evolence introduces collagen back into the market. Previously, collagen based products either required allergy testing (e.g., Zyderm/Zyplast) or were relatively short in its duration of effect (e.g., CosmoDerm/CosmoPlast). If Evolence can demonstrate some superiority over the plethora of products currently available, it may gain some market share. However, to do so will require a tremendous marketing effort and potential financial incentives as well.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta
www.fda.gov
Healthways' Guidance Not So Healthy
www.forbes.com
Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise
www.nytimes.com
Hospital Death Rates Unveiled for First-Time Comparison
www.usatoday.com
Temozolomide And Thalidomide Combination Effective Against Malignant Melanoma Spread To CNS And White Blood Cell Count May Be Prognostic
www.medicalnewstoday.com
Dangers of Methadone Usage
August 28, 2008
Its all about the spin
August 21, 2008
Byetta sale will reduce after FAD alert
August 19, 2008
PCI numbers will not drop after Courage
August 19, 2008
Bad News (but not new news) for stents.
August 19, 2008

